公开(公告)号：US20230416391A1

公开(公告)日：2023-12-28

申请号：US18326605

申请日：2023-05-31

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Huang HUANG ,  Carol Elaine O'HEAR ,  Iris Tranthuyngan TO ,  Michael Ching-sun WEI ,  Shen YIN

IPC: C07K16/28 ,  A61K9/00 ,  A61K31/138 ,  A61K31/167 ,  A61K31/573 ,  A61K39/395 ,  A61P35/00

CPC classification number: C07K16/2887 ,  C07K16/2809 ,  A61K9/0019 ,  A61K31/138 ,  A61K31/167 ,  A61K31/573 ,  A61K39/3955 ,  A61P35/00 ,  C07K2317/31 ,  C07K2317/24 ,  A61K2039/55

Abstract: The present invention relates to the treatment of elderly subjects (e.g., subjects aged 65 years or older) having relapsed and/or refractory (R/R) non-Hodgkin's lymphoma (NHL). More specifically, the invention pertains to the treatment of subjects having an R/R NHL by intravenous administration of mosunetuzumab.

公开(公告)号：US20220411528A1

公开(公告)日：2022-12-29

申请号：US17744262

申请日：2022-05-13

Applicant: Genentech, Inc.

Inventor： Carol Elaine O'HEAR ,  Yasuhiro OKI ,  Iris Tranthuyngan TO

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder. More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.

公开(公告)号：US20220153842A1

公开(公告)日：2022-05-19

申请号：US17516979

申请日：2021-11-02

Applicant: Genentech, Inc.

Inventor： Chi-Chung LI ,  Carol Elaine O'HEAR ,  Stephen James SIMKO, III ,  Iris Tranthuyngan TO ,  Klara TOTPAL ,  Hong WANG ,  Michael C. WEI ,  Shen YIN ,  Brendan Christian BENDER ,  Xi CHEN ,  Yu-Waye CHU ,  Maria HRISTOPOULOS

IPC: C07K16/28 ,  C07K16/46 ,  A61K47/68 ,  A61P35/00

Abstract: The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.